Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy
- PMID: 30377197
- DOI: 10.1158/1078-0432.CCR-18-2819
Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy
Abstract
Systemic IL12 therapy has potent antitumor effects, but clinical delivery of this potent cytokine has been complicated by systemic toxicity. A novel strategy to deliver IL12 to the tumor microenvironment appears promising in a first-in-human study, appearing to stimulate tumor-specific adaptive immune responses with minimal systemic toxicity.See related article by Strauss et al., p. 99.
©2018 American Association for Cancer Research.
Comment on
-
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21. Clin Cancer Res. 2019. PMID: 30131389 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources